【Delayed】Announcement on revision of financial forecast

Home Corporate Guide Message from the president Corporate Data Corporate History Corporate Executives Directions to Takara Bio Sustainability Initiatives Business Outline News Release Investor Relstions Management Policy Financial Data IR Library Stock Information IR Calendar IR News Disclosure Policy FAQ Contact IR User Guide Products Site About Us Business Outline News Release Investor Relstions Japanese... Read more

【Delayed】Consolidated Financial Statements for the First Quarter Ended June 30, 2020 FY2021 (April 1, 2020 – June 30, 2020)

Home Corporate Guide Message from the president Corporate Data Corporate History Corporate Executives Directions to Takara Bio Sustainability Initiatives Business Outline News Release Investor Relstions Management Policy Financial Data IR Library Stock Information IR Calendar IR News Disclosure Policy FAQ Contact IR User Guide Products Site About Us Business Outline News Release Investor Relstions Japanese... Read more

Roche announces FDA authorisation for the first Epstein-Barr virus quantitative test on the cobas 6800/8800 Systems to improve care for transplant patients

Basel, 5 August 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has authorised the cobas® EBV test. This is the first quantitative in vitro diagnostic test for Epstein-Barr virus (EBV) DNA in the United States. This authorisation gives healthcare professionals a key tool in monitoring... Read more

Luminex Corporation Reports Second Quarter 2020 Results

Delivers Accelerated Organic Growth and Profitability AUSTIN, Texas, Aug. 4, 2020 /PRNewswire/ — Luminex Corporation (Nasdaq: LMNX) today announced results for its second quarter ended June 30, 2020. All amounts in this release are in conformity with U.S. generally accepted accounting principles (“GAAP”). CURRENT FINANCIAL HIGHLIGHTS Total revenue for the second quarter of $109.5M, a 32%... Read more

The United States Court of Appeals for the Federal Circuit Affirms that 10x Genomics Willfully Infringed Bio-Rad U.S. Patent and Upholds Lower Court’s Award of Damages

HERCULES, Calif. –Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, announced that the The United States Court of Appeals for the Federal Circuit today affirmed that 10x Genomics willfully infringed U.S. Patent 8,889,083, exclusively licensed to Bio-Rad from the University of Chicago. The Appeals Court upheld... Read more

Fluidigm and De Novo Software to Offer Mass Cytometry Customers a Streamlined Solution for Data Analysis

License for De Novo Software’s FCS Express 7 Flow to be Provided to Customers Purchasing Fluidigm Helios and Hyperion Imaging Systems SOUTH SAN FRANCISCO, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) — Fluidigm Corporation (Nasdaq: FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced a distribution agreement with De Novo Software™... Read more

Brooks to Participate in the Needham Virtual SemiCap and EDA Investor Conference

CHELMSFORD, Mass., Aug. 4, 2020 /PRNewswire/ — Brooks Automation, Inc. (Nasdaq:BRKS) announced today that company management will participate in the Needham Virtual SemiCap and Electronic Design Automation Conference on Thursday, August 13, 2020 at 9:30 a.m. ET.  The 40-minute session will be webcast live via the Brooks investor relations website at www.brooks.investorroom.com/events. About Brooks AutomationBrooks... Read more